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Background: Pulmonary hypertension (PH) frequently co-exists with severe aortic
valve stenosis (AS) and PH severity has been shown to predict long-term outcomes
after transcatheter aortic valve implantation (TAVI). The impact of PH etiology on
clinical outcomes after TAVI is unknown.
Methods: Of 606 consecutive patients undergoing TAVI, 433 (71.4%) patients with
severe AS and a pre-procedural right heart catheterization were assessed. Patients were
dichotomized according to whether PH was present (mean pulmonary artery [PA]
pressure 25mmHg) (n¼325) or not (n¼108). PH patients were further dichotomized
by left-ventricular end-diastolic pressure (LVEDP) into post-capillary (LVEDP >15
mmHG; n¼269) and pre-capillary groups (LVEDP 15 mmHg; n¼56). Finally, post-
capillary PH patients were divided into passive (n¼133) and reactive (n¼136) sub-
groups according to whether the transpulmonary gradient was normal (12mmHg) or
elevated (>12mmHg). Primary-endpoint was all-cause mortality at one year.
Results: PH was present in 325/433 (75%) patients and was predominantly post-
capillary (n¼269/325; 82%). Compared with baseline, PA systolic pressures imme-
diately improved after TAVI in post-capillary reactive (55.314.4 vs 48.415.5
mmHg, p< 0.001), but not pre-capillary (49.012.6 vs 51.614.3, p¼0.36) patients.
As compared with no PH, a higher rate of one-year mortality was observed in both
pre-capillary (hazard ratio [HR] 2.30, 95% conﬁdence interval [CI] 1.02-5.22,
p¼0.046) and reactive (HR 2.63, 95% CI 1.33-5.20, p¼0.006) but not passive PH
patients (p¼0.43). Following adjustment, reactive PH remained an independent pre-
dictor of one year mortality after TAVI (HR 2.52, p¼0.01).
Conclusions: Hemodynamic stratiﬁcation of PH by etiology predicts acute response
to treatment and long-term mortality after TAVI.
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Background: Conventional redo aortic valve replacement (AVR) is associated with
high mortality and morbidity, particularly in elderly patients. Transcatheter aortic
valve implantation (TAVI) is a less invasive and potentially lower-risk therapeutic
option. We sought to assess outcome of Valve-in-Valve (ViV) TAVI for failing
stentless AVR performed at our institution.
Methods: All 22 patients undergoing 22 ViV TAVI for failing stentless AVR per-
formed at our centre were included. Mean age 7412 years, logistic EuroScore
3810, all NYHA Class III/IV, 41% had chronic kidney disease, 36% had ascending
aorta calciﬁcation, 32% had patent coronary bypass grafts, 27% had previous PCI,
14% had pulmonary disease (TLCO < 30%), and 14% had previous stroke. Original
implant date ranged 1990 to 2006. All patients had severe aortic regurgitation (AR)
due to failing homograft (17), Toronto (3), Freestyle (1), or native re-suspended aortic
valve (1). Mean left ventricular ejection fraction was 5719%.
Results: ViV TAVI was performed electively in 7, urgently in 13, and emergently in 2
cases. All received a CoreValve (23mm device in 2, 26mm in 13, 29mm in 6, 31mm in
1). Access route was transfemoral (19), subclavian (2), and direct aortic (1). The device
was deployed too high in 1 case and too low in 2, necessitating TAVI-in-TAVI. In
2 cases, the device migrated high prior to full deployment, requiring lower re-
deployment. In 1 case, the device embolized into ascending aorta and required surgical
removal. 30-day mortality was 0%. Based on VARC-II deﬁnitions, rate of myocardial
infarction, tamponade, stroke, bleeding, acute kidney injury, and major vascular
complications were all 0%. New pacemaker implantation occurred in 14%. Para-
valvular AR was absent in 4, mild in 15, mild-moderate in 3. Average length of hospital
stay was 96 days, and all patients were discharged home. At long-term (1-55 month)
follow-up, 19 patients remained alive (3 deaths; 65 days, 7 months, 9 months).
Conclusions: ViV TAVI may be performed in high-risk patients with failing
stentless AVR. Lack of ﬂuroscopic markers increases risk of valve migration and
embolization. Despite this, 30-day mortality was 0%, with low morbidity, and reso-
lution of AR.
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Background: Transfemoral aortic valve implantation (TAVI) requires large bore
catheters. Access site and vascular complications, therefore are of concern. Beside
major vascular complications, post-TAVI pseudoaneurysm formation (PAF) is a
frequent minor vascular complication. The aim of the study was to compare the
incidence of post-TAVI PAF between the CoreValve (CV) using the St.Jude 18-F-
sheath and the Edwards Sapien XT valve (ESV) using the 16-20 F Esheath.
Methods: Between April 2010 and December 2013, 448 pts (age 81.2  0.4 years)
with high surgical risk (Euroscore 24.3  0.8%) underwent successfully TAVI in local
anesthesia using either the CV (23,26,29,31mm) or the ESV (23, 26, 29mm). Closure
of the access site was perfomed in all pts by using the ProStar XL 10 suture device. All
TAVI pts (357 CV and 91 ESV) were examined serially the ﬁrst 5 days (day 1-3 and 5
post-TAVI) after the procedure by ultrasound (US) for clinically silent vascular
complications. In case of PAF, ultrasound-guided manual compression was done
followed by compression bandage for another 24 h.
Results: In 26 pts (5.6%) we observed major vascular complication after TAVI (19
[5.3 %] after CV and 7 [7.7%] after ESV, p¼0.261). Seven of these 26 pts (26.9%)
had to be treated surgically. In 78 pts (17.4%) we observed post-TAVI PAF, which
occurred signiﬁcantly more frequently after implantation of the ESV than after im-
plantation of the CV (19/91 [33.0%] versus 59/357 [16.6%], p¼0.01). However in
total only 5 /78 (6.4 %) patients with PAFs had to be treated surgically , the others
were treated either by ultrasound guided manual compression or conservatively if
smaller than 1 cm.
Conclusions: Clinically silent PAF detected by routine US is a frequent post-TAVI
minor vascular complication which is more likely to occur after ESV using the
Esheath than after CV. Although US-guided compression is highly effective, further
miniaturisation of TAVI devices and modiﬁcation of the Esheath design might help to
eliminate post-TAVI PAF.
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Background: The successful TAVI outcomes are partly driven by the operator skills,
expertise & experience. The impact of “learning curve” on one year all-cause mor-
tality is not well understood.
Methods: Registry records of 188 consecutive TAVI cases in a UK tertiary cardiac
centre (2007-2013) were reviewed using patient-level data. One year all-cause mor-
tality data was collated with demographic, risk proﬁle and TAVI procedural infor-
mation. Kaplan-Meier analysis was used to compare mortality among the ﬁrst 60
patients(learning curve group,GP1) with age, gender matched sequential groups(GP2,
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